Abstract
OBJECTIVES: This study was carried out to test the hypothesis that the hepatic safety profile of prolonged high-dose oral naltrexone (150 mg/d) is acceptable if over-the-counter analgesic use is restricted. METHODS: Data from 41 consecutive outpatients with impulse-control disorder receiving naltrexone therapy were analyzed. RESULTS: The mean treatment duration was 328 days and the mean naltrexone dose was 142 mg/d. Pretherapy/posttherapy mean aspartate transaminase and alanine transaminase levels in the naltrexone-alone group were 21.79/22.54 and 21.74/21.49 U, respectively (all within reference range). CONCLUSIONS: Although limited in scope, these findings support the hypothesis that long-term use of high-dose oral naltrexone is safe in otherwise healthy patients with impulse-control disorders who restrict their intake of acetaminophen, aspirin, or nonaspirin nonsteroidal anti-inflammatory drugs (NSAID). However, confirming studies are needed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 77-79 |
| Number of pages | 3 |
| Journal | Clinical Neuropharmacology |
| Volume | 29 |
| Issue number | 2 |
| DOIs | |
| State | Published - Mar 1 2006 |
Fingerprint
Keywords
- Alanine transaminase
- Aspartate transaminase
- Hepatotoxicity
- Impulse-control disorders
- NSAID
- Naltrexone
- Nonsteroidal anti-inflammatory drugs
- Pathologic gambling disorder
Cite this
Safety of high-dose naltrexone treatment : Hepatic transaminase profiles among outpatients. / Kim, Suck W; Grant, Jon E.; Yoon, Gihyun; Williams, Kyle A.; Remmel, Rory P.
In: Clinical Neuropharmacology, Vol. 29, No. 2, 01.03.2006, p. 77-79.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Safety of high-dose naltrexone treatment
T2 - Hepatic transaminase profiles among outpatients
AU - Kim, Suck W
AU - Grant, Jon E.
AU - Yoon, Gihyun
AU - Williams, Kyle A.
AU - Remmel, Rory P
PY - 2006/3/1
Y1 - 2006/3/1
N2 - OBJECTIVES: This study was carried out to test the hypothesis that the hepatic safety profile of prolonged high-dose oral naltrexone (150 mg/d) is acceptable if over-the-counter analgesic use is restricted. METHODS: Data from 41 consecutive outpatients with impulse-control disorder receiving naltrexone therapy were analyzed. RESULTS: The mean treatment duration was 328 days and the mean naltrexone dose was 142 mg/d. Pretherapy/posttherapy mean aspartate transaminase and alanine transaminase levels in the naltrexone-alone group were 21.79/22.54 and 21.74/21.49 U, respectively (all within reference range). CONCLUSIONS: Although limited in scope, these findings support the hypothesis that long-term use of high-dose oral naltrexone is safe in otherwise healthy patients with impulse-control disorders who restrict their intake of acetaminophen, aspirin, or nonaspirin nonsteroidal anti-inflammatory drugs (NSAID). However, confirming studies are needed.
AB - OBJECTIVES: This study was carried out to test the hypothesis that the hepatic safety profile of prolonged high-dose oral naltrexone (150 mg/d) is acceptable if over-the-counter analgesic use is restricted. METHODS: Data from 41 consecutive outpatients with impulse-control disorder receiving naltrexone therapy were analyzed. RESULTS: The mean treatment duration was 328 days and the mean naltrexone dose was 142 mg/d. Pretherapy/posttherapy mean aspartate transaminase and alanine transaminase levels in the naltrexone-alone group were 21.79/22.54 and 21.74/21.49 U, respectively (all within reference range). CONCLUSIONS: Although limited in scope, these findings support the hypothesis that long-term use of high-dose oral naltrexone is safe in otherwise healthy patients with impulse-control disorders who restrict their intake of acetaminophen, aspirin, or nonaspirin nonsteroidal anti-inflammatory drugs (NSAID). However, confirming studies are needed.
KW - Alanine transaminase
KW - Aspartate transaminase
KW - Hepatotoxicity
KW - Impulse-control disorders
KW - NSAID
KW - Naltrexone
KW - Nonsteroidal anti-inflammatory drugs
KW - Pathologic gambling disorder
UR - http://www.scopus.com/inward/record.url?scp=33646934982&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646934982&partnerID=8YFLogxK
U2 - 10.1097/00002826-200603000-00004
DO - 10.1097/00002826-200603000-00004
M3 - Article
C2 - 16614539
AN - SCOPUS:33646934982
VL - 29
SP - 77
EP - 79
JO - Clinical Neuropharmacology
JF - Clinical Neuropharmacology
SN - 0362-5664
IS - 2
ER -